The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9.Stay Ahead of the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...